アトピー性皮膚炎治療薬の世界市場規模、シェア、産業動向分析レポート：投与経路別、クラス別（生物製剤、カルシニューリン阻害剤、コルチコステロイド、PDE4阻害剤）、地域別展望および予測、2022年～2028年

アトピー性皮膚炎治療薬の世界市場規模は、2028年までに220億米ドルに達し、予測期間中にCAGR 9.2%の市場成長率で上昇すると予測されています。

アトピー性皮膚炎は、年齢を問わず発症しますが、通常は小児期に初めて発症し、その重症度は時間と共に変化します。1歳未満の幼児では、体の多くの部分に影響が出る可能性があります。膝や肘の内側は、子供の年齢とともに最も頻繁に影響を受ける部分です。大人では、手足に多く見られます。

患部を掻くと症状が悪化し、掻いている人は皮膚感染症になる可能性が高くなります。アトピー性皮膚炎は、喘息や花粉症につながることも多いです。病気を悪化させるものを避ける、定期的な入浴と保湿クリームの使用、症状が出たときのステロイドクリームの使用、かゆみを抑える薬などの治療が必要です。

ウールの衣服、石鹸、香料、ほこり、塩素、タバコの煙などは、頻繁に悪化させるいくつかのものです。人によっては、光線療法が有効な場合もあります。他の治療が無効な場合は、ステロイドの錠剤やカルシニューリン阻害剤をベースにしたローションが採用されることがあります。細菌感染がある場合は、抗生物質（経口または局所）の投与が必要です。食物アレルギーが検出された場合のみ、食事療法が必要となります。

COVID-19の影響分析

コロナウイルスは、社会的な交流から医療や外の世界の見方に至るまで、あらゆるものを混乱させ、世界の規模で人々の生活に問題を引き起こしています。あらゆる産業で、パンデミックの流行による利益や生産高の減少が起きています。しかし、アトピー性皮膚炎の治療市場は、患者の通院が不規則であることから、大きな影響が予想されます。このような状況下でも、患者の大半は医師の診察を受けずに一般的な治療や追加的な治療を受けることができるため、テレデマトロジーは成長を続けているのです。

市場の成長要因

生物学的製剤の需要拡大

皮膚科疾患、特にアトピー性皮膚炎の治療は、皮膚科における生物学的製剤の使用により変化してきました。生物学的製剤はアトピー性皮膚炎に対して良好な反応を示し、全体的な生活の質を向上させることができました。その結果、現在ではアトピー性皮膚炎に対する生物学的製剤の治療に対する需要が高まっています。今後数年間は、おそらくこのパターンが続くと思われます。アトピー性皮膚炎の治療薬として承認されている生物学的製剤は、今のところ1つだけです。現在、多くの製品が第II相臨床試験を実施中であり、おそらく近いうちに承認されるであろう。

アトピー性皮膚炎の有病率の上昇

アトピー性皮膚炎治療薬の市場を牽引する主な要因は、世界のアトピー性皮膚炎患者の増加であると予想されます。多くの人々がアトピー性皮膚炎に苦しんでおり、今後数年間でさらに増加すると予想されています。アトピー性皮膚炎は、地理的条件、気候条件、社会経済水準、ライフスタイル、年齢、性別、遺伝、個人の行動などが、世界中の皮膚科疾患の有病率に影響を及ぼしていると言われています。アトピー性皮膚炎は、日常的にアレルギーと付き合わなければなりません。

市場抑制要因

局所用ステロイドの副作用

4週間未満のステロイド外用薬治療は、リスクもトラブルもないことが多いです。ステロイド外用剤の長期使用や、刺激の強いステロイドの短時間投与を頻繁に繰り返すと、問題が生じることがあります。主な問題は、強力なステロイドの長期使用です。軽度のステロイド外用剤では、ほとんど副作用はありません。ステロイド外用剤には、局所的な副作用と全身的な副作用があります。全身性とは、個人全体に影響する問題で、局所性とは、皮膚の特定の部分に影響する問題です。

クラスの展望

クラスに基づいて、アトピー性皮膚炎治療薬市場は、コルチコステロイド、カルシニューリン阻害剤、PDE4阻害剤、生物製剤、その他に区分されます。2021年、副腎皮質ホルモンセグメントは、アトピー性皮膚炎治療薬市場においてかなりの収益シェアを獲得しています。炎症性腸疾患、発疹、喘息などの多くの症状は、コルチゾン、ヒドロコルチゾン、プレドニゾンなどのコルチコステロイド薬でうまく治療することができます。

投与経路の展望

アトピー性皮膚炎治療薬市場は、投与経路に基づき、外用剤、注射剤、経口剤に細分化されます。2021年、アトピー性皮膚炎治療薬市場では、注射剤が最大の収益シェアを占めています。これは、デュピルマブのような注射剤の人気が高まっているためです。Tofacitinibとruxolitinibは、臨床試験で研究されている他の注射用生物製剤です。近い将来、生物学的製剤はADの治療状況を変化させると予想されています。

地域別の展望

地域別に見ると、アトピー性皮膚炎治療薬市場は、北米、欧州、アジア太平洋、LAMEAで分析されています。2021年には、北米地域が最も高い収益シェアを獲得し、アトピー性皮膚炎治療薬市場をリードしました。確立された研究開発インフラと親切な償還規則が利用可能であることが、この地域の持続的な優位性に寄与する2つの主要因です。また、この分野の研究の急速な進展に伴い、規制や償還の環境も常に変化しています。

市場参入企業がとる主な戦略は買収です。カーディナルマトリックスで提示された分析によると、アトピー性皮膚炎治療薬市場では、ファイザーとノバルティスAGが先行しています。AbbVie, Inc.、Sanofi SA、Regeneron Pharmaceuticals Inc.などの企業は、アトピー性皮膚炎治療薬市場における主要な革新者の一部です。

目次

第1章 市場の範囲と調査手法

• 市場の定義
• 目的
• 市場規模
• セグメンテーション
  • アトピー性皮膚炎治療薬の世界市場：投与経路別
  • アトピー性皮膚炎治療薬の世界市場：クラス別
  • アトピー性皮膚炎治療薬の世界市場、地域別
• 調査手法

第2章 市場概要

• イントロダクション
  • 概要説明
    • 市場の構成とシナリオ
• 市場に影響を与える主な要因
  • 市場促進要因
  • 市場の抑制要因

第3章 競合分析-世界

• KBVカーディナルマトリックス
• 最近の業界全体の戦略的展開
  • 買収と合併
  • 承認とトライアル
• 主要成功戦略
  • 主要な主要戦略：パーセンテージ分布（2018-2022年）
  • 主要な戦略的動き：（買収・合併：2018年、9月～2022年、10月）主要プレイヤー

第4章 アトピー性皮膚炎治療薬の世界市場：投与経路別

• 注射剤の世界市場：地域別
• 経口剤の世界市場：地域別
• 外用剤の世界市場：地域別

第5章 アトピー性皮膚炎治療薬の世界市場：クラス別

• 生物製剤の世界市場：地域別
• カルシニューリン阻害剤の世界市場：地域別
• コルチコステロイドの世界市場：地域別
• PDE4阻害剤の世界市場：地域別
• その他の地域別世界市場

第6章 アトピー性皮膚炎治療薬の世界市場：地域別

• 北米
  • 北米のアトピー性皮膚炎治療薬の国別市場
    • 米国
    • カナダ
    • メキシコ
    • その他北米地域
• 欧州
  • 欧州のアトピー性皮膚炎治療薬国別市場
    • ドイツ
    • 英国
    • フランス
    • ロシア
    • スペイン
    • イタリア
    • その他欧州
• アジア太平洋地域
  • アジア太平洋地域のアトピー性皮膚炎治療薬市場：国別
    • 中国
    • 日本
    • インド
    • 韓国
    • シンガポール
    • マレーシア
    • その他アジア太平洋地域
• LAMEA
  • LAMEAアトピー性皮膚炎治療薬市場：国別
    • ブラジル
    • アルゼンチン
    • UAE
    • サウジアラビア
    • 南アフリカ
    • ナイジェリア
    • その他のLAMEA

第7章 企業プロファイル

• Pfizer, Inc.
• Novartis AG
• Sanofi S.A
• LEO Pharma A/S
• Incyte Corporation
• AbbVie, Inc.
• Regeneron Pharmaceuticals, Inc.
• Eli Lilly And Company
• Otsuka Pharmaceutical Co., Ltd.
• Galderma S.A

LIST OF TABLES

• TABLE 1 Global Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 2 Global Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 3 Acquisition and Mergers- Atopic Dermatitis Drugs Market
• TABLE 4 Approvals and trials - Atopic Dermatitis Drugs Market
• TABLE 5 Global Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 6 Global Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 7 Global Injectable Market by Region, 2018 - 2021, USD Million
• TABLE 8 Global Injectable Market by Region, 2022 - 2028, USD Million
• TABLE 9 Global Oral Market by Region, 2018 - 2021, USD Million
• TABLE 10 Global Oral Market by Region, 2022 - 2028, USD Million
• TABLE 11 Global Topical Market by Region, 2018 - 2021, USD Million
• TABLE 12 Global Topical Market by Region, 2022 - 2028, USD Million
• TABLE 13 Global Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 14 Global Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 15 Global Biologics Market by Region, 2018 - 2021, USD Million
• TABLE 16 Global Biologics Market by Region, 2022 - 2028, USD Million
• TABLE 17 Global Calcineurin Inhibitors Market by Region, 2018 - 2021, USD Million
• TABLE 18 Global Calcineurin Inhibitors Market by Region, 2022 - 2028, USD Million
• TABLE 19 Global Corticosteroids Market by Region, 2018 - 2021, USD Million
• TABLE 20 Global Corticosteroids Market by Region, 2022 - 2028, USD Million
• TABLE 21 Global PDE4 Inhibitors Market by Region, 2018 - 2021, USD Million
• TABLE 22 Global PDE4 Inhibitors Market by Region, 2022 - 2028, USD Million
• TABLE 23 Global Others Market by Region, 2018 - 2021, USD Million
• TABLE 24 Global Others Market by Region, 2022 - 2028, USD Million
• TABLE 25 Global Atopic Dermatitis Drugs Market by Region, 2018 - 2021, USD Million
• TABLE 26 Global Atopic Dermatitis Drugs Market by Region, 2022 - 2028, USD Million
• TABLE 27 North America Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 28 North America Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 29 North America Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 30 North America Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 31 North America Injectable Market by Country, 2018 - 2021, USD Million
• TABLE 32 North America Injectable Market by Country, 2022 - 2028, USD Million
• TABLE 33 North America Oral Market by Country, 2018 - 2021, USD Million
• TABLE 34 North America Oral Market by Country, 2022 - 2028, USD Million
• TABLE 35 North America Topical Market by Country, 2018 - 2021, USD Million
• TABLE 36 North America Topical Market by Country, 2022 - 2028, USD Million
• TABLE 37 North America Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 38 North America Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 39 North America Biologics Market by Country, 2018 - 2021, USD Million
• TABLE 40 North America Biologics Market by Country, 2022 - 2028, USD Million
• TABLE 41 North America Calcineurin Inhibitors Market by Country, 2018 - 2021, USD Million
• TABLE 42 North America Calcineurin Inhibitors Market by Country, 2022 - 2028, USD Million
• TABLE 43 North America Corticosteroids Market by Country, 2018 - 2021, USD Million
• TABLE 44 North America Corticosteroids Market by Country, 2022 - 2028, USD Million
• TABLE 45 North America PDE4 Inhibitors Market by Country, 2018 - 2021, USD Million
• TABLE 46 North America PDE4 Inhibitors Market by Country, 2022 - 2028, USD Million
• TABLE 47 North America Others Market by Country, 2018 - 2021, USD Million
• TABLE 48 North America Others Market by Country, 2022 - 2028, USD Million
• TABLE 49 North America Atopic Dermatitis Drugs Market by Country, 2018 - 2021, USD Million
• TABLE 50 North America Atopic Dermatitis Drugs Market by Country, 2022 - 2028, USD Million
• TABLE 51 US Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 52 US Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 53 US Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 54 US Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 55 US Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 56 US Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 57 Canada Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 58 Canada Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 59 Canada Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 60 Canada Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 61 Canada Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 62 Canada Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 63 Mexico Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 64 Mexico Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 65 Mexico Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 66 Mexico Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 67 Mexico Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 68 Mexico Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 69 Rest of North America Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 70 Rest of North America Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 71 Rest of North America Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 72 Rest of North America Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 73 Rest of North America Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 74 Rest of North America Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 75 Europe Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 76 Europe Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 77 Europe Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 78 Europe Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 79 Europe Injectable Market by Country, 2018 - 2021, USD Million
• TABLE 80 Europe Injectable Market by Country, 2022 - 2028, USD Million
• TABLE 81 Europe Oral Market by Country, 2018 - 2021, USD Million
• TABLE 82 Europe Oral Market by Country, 2022 - 2028, USD Million
• TABLE 83 Europe Topical Market by Country, 2018 - 2021, USD Million
• TABLE 84 Europe Topical Market by Country, 2022 - 2028, USD Million
• TABLE 85 Europe Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 86 Europe Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 87 Europe Biologics Market by Country, 2018 - 2021, USD Million
• TABLE 88 Europe Biologics Market by Country, 2022 - 2028, USD Million
• TABLE 89 Europe Calcineurin Inhibitors Market by Country, 2018 - 2021, USD Million
• TABLE 90 Europe Calcineurin Inhibitors Market by Country, 2022 - 2028, USD Million
• TABLE 91 Europe Corticosteroids Market by Country, 2018 - 2021, USD Million
• TABLE 92 Europe Corticosteroids Market by Country, 2022 - 2028, USD Million
• TABLE 93 Europe PDE4 Inhibitors Market by Country, 2018 - 2021, USD Million
• TABLE 94 Europe PDE4 Inhibitors Market by Country, 2022 - 2028, USD Million
• TABLE 95 Europe Others Market by Country, 2018 - 2021, USD Million
• TABLE 96 Europe Others Market by Country, 2022 - 2028, USD Million
• TABLE 97 Europe Atopic Dermatitis Drugs Market by Country, 2018 - 2021, USD Million
• TABLE 98 Europe Atopic Dermatitis Drugs Market by Country, 2022 - 2028, USD Million
• TABLE 99 Germany Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 100 Germany Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 101 Germany Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 102 Germany Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 103 Germany Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 104 Germany Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 105 UK Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 106 UK Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 107 UK Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 108 UK Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 109 UK Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 110 UK Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 111 France Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 112 France Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 113 France Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 114 France Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 115 France Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 116 France Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 117 Russia Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 118 Russia Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 119 Russia Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 120 Russia Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 121 Russia Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 122 Russia Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 123 Spain Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 124 Spain Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 125 Spain Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 126 Spain Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 127 Spain Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 128 Spain Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 129 Italy Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 130 Italy Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 131 Italy Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 132 Italy Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 133 Italy Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 134 Italy Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 135 Rest of Europe Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 136 Rest of Europe Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 137 Rest of Europe Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 138 Rest of Europe Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 139 Rest of Europe Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 140 Rest of Europe Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 141 Asia Pacific Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 142 Asia Pacific Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 143 Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 144 Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 145 Asia Pacific Injectable Market by Country, 2018 - 2021, USD Million
• TABLE 146 Asia Pacific Injectable Market by Country, 2022 - 2028, USD Million
• TABLE 147 Asia Pacific Oral Market by Country, 2018 - 2021, USD Million
• TABLE 148 Asia Pacific Oral Market by Country, 2022 - 2028, USD Million
• TABLE 149 Asia Pacific Topical Market by Country, 2018 - 2021, USD Million
• TABLE 150 Asia Pacific Topical Market by Country, 2022 - 2028, USD Million
• TABLE 151 Asia Pacific Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 152 Asia Pacific Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 153 Asia Pacific Biologics Market by Country, 2018 - 2021, USD Million
• TABLE 154 Asia Pacific Biologics Market by Country, 2022 - 2028, USD Million
• TABLE 155 Asia Pacific Calcineurin Inhibitors Market by Country, 2018 - 2021, USD Million
• TABLE 156 Asia Pacific Calcineurin Inhibitors Market by Country, 2022 - 2028, USD Million
• TABLE 157 Asia Pacific Corticosteroids Market by Country, 2018 - 2021, USD Million
• TABLE 158 Asia Pacific Corticosteroids Market by Country, 2022 - 2028, USD Million
• TABLE 159 Asia Pacific PDE4 Inhibitors Market by Country, 2018 - 2021, USD Million
• TABLE 160 Asia Pacific PDE4 Inhibitors Market by Country, 2022 - 2028, USD Million
• TABLE 161 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
• TABLE 162 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
• TABLE 163 Asia Pacific Atopic Dermatitis Drugs Market by Country, 2018 - 2021, USD Million
• TABLE 164 Asia Pacific Atopic Dermatitis Drugs Market by Country, 2022 - 2028, USD Million
• TABLE 165 China Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 166 China Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 167 China Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 168 China Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 169 China Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 170 China Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 171 Japan Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 172 Japan Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 173 Japan Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 174 Japan Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 175 Japan Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 176 Japan Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 177 India Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 178 India Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 179 India Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 180 India Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 181 India Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 182 India Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 183 South Korea Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 184 South Korea Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 185 South Korea Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 186 South Korea Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 187 South Korea Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 188 South Korea Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 189 Singapore Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 190 Singapore Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 191 Singapore Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 192 Singapore Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 193 Singapore Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 194 Singapore Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 195 Malaysia Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 196 Malaysia Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 197 Malaysia Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 198 Malaysia Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 199 Malaysia Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 200 Malaysia Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 201 Rest of Asia Pacific Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 202 Rest of Asia Pacific Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 203 Rest of Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 204 Rest of Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 205 Rest of Asia Pacific Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 206 Rest of Asia Pacific Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 207 LAMEA Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 208 LAMEA Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 209 LAMEA Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 210 LAMEA Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 211 LAMEA Injectable Market by Country, 2018 - 2021, USD Million
• TABLE 212 LAMEA Injectable Market by Country, 2022 - 2028, USD Million
• TABLE 213 LAMEA Oral Market by Country, 2018 - 2021, USD Million
• TABLE 214 LAMEA Oral Market by Country, 2022 - 2028, USD Million
• TABLE 215 LAMEA Topical Market by Country, 2018 - 2021, USD Million
• TABLE 216 LAMEA Topical Market by Country, 2022 - 2028, USD Million
• TABLE 217 LAMEA Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 218 LAMEA Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 219 LAMEA Biologics Market by Country, 2018 - 2021, USD Million
• TABLE 220 LAMEA Biologics Market by Country, 2022 - 2028, USD Million
• TABLE 221 LAMEA Calcineurin Inhibitors Market by Country, 2018 - 2021, USD Million
• TABLE 222 LAMEA Calcineurin Inhibitors Market by Country, 2022 - 2028, USD Million
• TABLE 223 LAMEA Corticosteroids Market by Country, 2018 - 2021, USD Million
• TABLE 224 LAMEA Corticosteroids Market by Country, 2022 - 2028, USD Million
• TABLE 225 LAMEA PDE4 Inhibitors Market by Country, 2018 - 2021, USD Million
• TABLE 226 LAMEA PDE4 Inhibitors Market by Country, 2022 - 2028, USD Million
• TABLE 227 LAMEA Others Market by Country, 2018 - 2021, USD Million
• TABLE 228 LAMEA Others Market by Country, 2022 - 2028, USD Million
• TABLE 229 LAMEA Atopic Dermatitis Drugs Market by Country, 2018 - 2021, USD Million
• TABLE 230 LAMEA Atopic Dermatitis Drugs Market by Country, 2022 - 2028, USD Million
• TABLE 231 Brazil Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 232 Brazil Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 233 Brazil Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 234 Brazil Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 235 Brazil Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 236 Brazil Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 237 Argentina Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 238 Argentina Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 239 Argentina Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 240 Argentina Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 241 Argentina Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 242 Argentina Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 243 UAE Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 244 UAE Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 245 UAE Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 246 UAE Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 247 UAE Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 248 UAE Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 249 Saudi Arabia Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 250 Saudi Arabia Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 251 Saudi Arabia Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 252 Saudi Arabia Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 253 Saudi Arabia Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 254 Saudi Arabia Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 255 South Africa Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 256 South Africa Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 257 South Africa Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 258 South Africa Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 259 South Africa Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 260 South Africa Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 261 Nigeria Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 262 Nigeria Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 263 Nigeria Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 264 Nigeria Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 265 Nigeria Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 266 Nigeria Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 267 Rest of LAMEA Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
• TABLE 268 Rest of LAMEA Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
• TABLE 269 Rest of LAMEA Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
• TABLE 270 Rest of LAMEA Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
• TABLE 271 Rest of LAMEA Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
• TABLE 272 Rest of LAMEA Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
• TABLE 273 Key Information - Pfizer, Inc.
• TABLE 274 Key Information - Novartis AG
• TABLE 275 Key Information - Sanofi S.A.
• TABLE 276 key information - LEO Pharma A/S
• TABLE 277 Key Information - INCYTE CORPORATION
• TABLE 278 Key information - AbbVie, Inc.
• TABLE 279 Key Information - Regeneron Pharmaceuticals, Inc.
• TABLE 280 Key Information - Eli Lilly And Company
• TABLE 281 key information - Otsuka Pharmaceutical Co., Ltd.
• TABLE 282 Key Information - Galderma S.A.

List of Figures

• FIG 1 Methodology for the research
• FIG 2 KBV Cardinal Matrix
• FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
• FIG 4 Key Strategic Move: (Acquisitions and Mergers: 2018, SeP - 2022, Oct) Leading Players
• FIG 5 Global Atopic Dermatitis Drugs Market Share by Route of Administration, 2021
• FIG 6 Global Atopic Dermatitis Drugs Market Share by Route of Administration, 2028
• FIG 7 Global Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2028, USD Million
• FIG 8 Global Atopic Dermatitis Drugs Market Share by Class, 2021
• FIG 9 Global Atopic Dermatitis Drugs Market Share by Class, 2028
• FIG 10 Global Atopic Dermatitis Drugs Market by Class, 2018 - 2028, USD Million
• FIG 11 Global Atopic Dermatitis Drugs Market Share by Region, 2021
• FIG 12 Global Atopic Dermatitis Drugs Market Share by Region, 2028
• FIG 13 Global Atopic Dermatitis Drugs Market by Region, 2018 - 2028, USD Million
• FIG 14 Recent strategies and developments: Pfizer, Inc.
• FIG 15 Recent strategies and developments: sanofi s.a.
• FIG 16 Recent strategies and developments: leo pharma a/s

The Global Atopic Dermatitis Drugs Market size is expected to reach $22 billion by 2028, rising at a market growth of 9.2% CAGR during the forecast period.

Eczema, commonly referred to as atopic dermatitis, is a skin ailment that affects the skin and results in itching, dryness, and inflammation. The illness has a potential for chronicity and occasionally flares up and spreads. Drugs for atopic dermatitis, such as atopic eczema steroids, are utilized to treat eczema, lessen itching, and treat other atopic dermatitis-related disorders.

Atopic dermatitis patients run the risk of acquiring asthma, hay fever, and food allergies. Regular moisturizing and other skin care practices help reduce itching and stop future outbreaks. Medicated lotions or ointments may also be used during treatment. It causes skin that is scratchy, red, swollen, and cracked. The damaged sites may leak a clear fluid that thickens over time.

Although the disorder can strike at any age, it usually first manifests in childhood and varies in severity throughout time. Much of the body may be impacted in youngsters under the age of one year. The areas on the inside of the knees and elbows are most frequently affected as kids age. Adults are more frequently afflicted in the hands and feet.

Scratching the affected regions makes the symptoms worse, and individuals who are scratching have a higher chance of developing skin infections. Atopic dermatitis frequently leads to the development of asthma or hay fever. Avoiding things that aggravate the illness, regular bathing followed by the use of moisturizing cream, using steroid creams when flare-ups happen, and drugs to relieve itching are all part of the treatment.

Wool garments, soaps, fragrances, dust, chlorine, and cigarette smoke are a few things that frequently aggravate it. Some people may benefit from phototherapy. If other treatments are ineffective, steroid tablets or lotions based on calcineurin inhibitors may occasionally be employed. If a bacterial infection manifests, antibiotics (by mouth or topically) could be required. Only if food allergies are detected are dietary modifications required.

COVID-19 Impact Analysis

The coronavirus is still creating trouble in people's lives on a worldwide scale, disrupting everything from social interactions to how they seek medical care and see the outside world. Every industry has experienced a profit or output decrease as a result of the pandemic epidemic. However, the market for treating atopic dermatitis has anticipated a substantial impact because of the irregularity of hospital visits by patients. Teledermatology has grown during the crisis when the majority of patients continue to receive generalized care and/or additional consultative therapies without seeing a doctor in person.

Market Growth Factors

Growing Demand For Biologics

The treatment of dermatological disorders, particularly atopic dermatitis, has changed as a result of the use of biologic drugs in dermatology. Biologics have demonstrated a good response to atopic dermatitis, improving the overall quality of life. As a result, there is now a greater demand for biologic treatments for atopic dermatitis. In the upcoming several years, this pattern is probably going to continue. For the time being, only one biologic product has been authorized for the treatment of atopic dermatitis. Many more are currently through phase II clinical studies and will probably be approved soon.

Rising Prevalence Of Atopic Dermatitis

The increasing prevalence of atopic dermatitis medications around the world is anticipated to be the main factor driving the market for atopic dermatitis medications. A large number of people suffer with atopic dermatitis which is expected to rise even more in upcoming years. Geographical location, climatic circumstances, socioeconomic level, lifestyle, age, gender, inheritance, and individual behaviors all have an impact on the prevalence of dermatological problems around the world. An individual with atopic dermatitis must deal with allergies on a daily basis.

Market Restraining Factors

Side Effects Of Topical Steroids

Topical steroid treatments lasting fewer than four weeks are often risk-free and trouble-free. Long-term topical steroid use or frequent repetition of short doses of harsher steroids may cause issues. The primary issue is the prolonged usage of potent steroids. Mild topical steroids rarely have side effects. Topical steroids may have local or systemic side effects. Systemic refers to an issue that affects the entire individual, whereas local refers to that particular area of skin.

Class Outlook

Based on class, the atopic dermatitis drugs market is segmented into corticosteroids, calcineurin inhibitors, PDE4 inhibitors, biologics and others. In 2021, the corticosteroids segment acquired a substantial revenue share in the atopic dermatitis drugs market. Many conditions, such as inflammatory bowel disease, rashes, and asthma, can be successfully treated with corticosteroid medications, such as cortisone, hydrocortisone, and prednisone.

Route Of Administration Outlook

On the basis of route of administration, the atopic dermatitis drugs market is fragmented into topical, injectable and oral. In 2021, the injectable segment held the largest revenue share in the atopic dermatitis drugs market. This is due to the rising popularity of injectable drugs like Dupilumab. Tofacitinib and ruxolitinib are other injectable biologics being studied in clinical trials. In the near future, biologics are anticipated to alter the therapy landscape for AD.

Regional Outlook

Region wise, the atopic dermatitis drugs market is analyzed across North America, Europe, Asia Pacific and LAMEA. In 2021, the North America region led the atopic dermatitis drugs market by generating the highest revenue share. The availability of a well-established R&D infrastructure and kind reimbursement rules are two major factors contributing to the region's sustained dominance. Additionally, the regulatory and reimbursement environment is constantly changing to keep up with the rapid advancement of research in this field.

The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Pfizer, Inc. and Novartis AG are the forerunners in the Atopic Dermatitis Drugs Market. Companies such as AbbVie, Inc., Sanofi SA, Regeneron Pharmaceuticals Inc. are some of the key innovators in Atopic Dermatitis Drugs Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer Inc., Sanofi SA, AbbVie Inc., Galderma S.A., Eli Lilly and Company, Leo Pharma A/S, Regeneron Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Novartis AG, and Incyte Corporation.

Recent Strategies Deployed in Atopic Dermatitis Drugs Market

Mergers and Acquisitions:

Oct-2022: Incyte completed the acquisition of Villaris Therapeutics, an asset-centric biopharmaceutical company. This acquisition would complement Incyte's current portfolio, providing Incyte the opportunity to improve treatment options for people with vitiligo, that leverage the expertise established in the dermatology space.

Jun-2022: Pfizer took over ReViral, a privately held, clinical-stage Biopharmaceutical Company. This acquisition further demonstrates Pfizer's commitment to advancing pioneering science both through its in-house expertise and work with leading, innovative companies - with the aim to deliver breakthroughs to patients suffering from severe infectious diseases.

Mar-2022: Pfizer completed the acquisition of Arena Pharmaceuticals, an American biopharmaceutical company. Through this acquisition, Pfizer would add the impressive experience and pipeline of Arena Pharmaceuticals to Pfizer's Inflammation & Immunology therapeutic area, helping the company further its purpose of developing breakthroughs to change the lives of those with immuno-inflammatory diseases.

Jan-2022: Galderma took over ALASTIN Skincare, a specialty aesthetics company. This acquisition aimed at enhancing Galderma's integrated dermatology platform with a comprehensive collection of scientifically-approved products for daily skincare regimens and peri-procedural use. Also, the acquisition would underscore Galderma's commitment to being the partner of choice for aesthetic professionals.

Dec-2021: AbbVie took over Soliton, a medical device company. The acquisition would complement Allergan Aesthetics' portfolio of non-invasive body contouring treatments to include a proven treatment for the appearance of cellulite.

Nov-2021: Sanofi completed the acquisition of Translate Bio, a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases. The acquisition support Sanofi's mRNA Center of Excellence, which plans to explore the potential of enhanced mRNA vaccines & other key areas that includes immunology, oncology, and rare diseases.

Nov-2021: Sanofi took over Kadmon Holdings, which operates as a biopharmaceutical company. This acquisition would strengthen the expansion & growth of the general medicines portfolio.

Jul-2019: LEO Pharma completed the acquisition of Bayer. LEO Pharma advances significantly towards its goal of helping 125 million patients by 2025. With this acquisition, the LEO considerably improve its size in key markets like Austria, Brazil, and South Africa - underlining its ambition to become a global leader in medical dermatology.

Approvals and Trials:

Oct-2022: LEO Pharma got European approval for Adtralza, a drug to treat moderate-to-severe AD in adolescents. The approval would address LEO's relentless commitment to bringing the latest treatment options for those living with atopic dermatitis. This approval enables LEO to address the unmet needs of a broader patient population as it looks forwards to work with key stakeholders across the Europe region.

Jun-2022: Sanofi got FDA approval for Dupixent, a biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood. The approval would enable the availability of Dupixent for young people with the disease.

Jan-2022: Pfizer got FDA approval for CIBINQO, an oral, once-daily, Janus kinase 1 (JAK1) inhibitor. CIBINQO would offer the treatment of adults living with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products. CIBINQO would provide an important latest oral option that would help those who have yet to find relief.

Jan-2022: AbbVie got FDA approval for RINVOQ, a once-daily oral option that can significantly enhance the debilitating itch & skin symptoms of atopic dermatitis. Through this acquisition, AbbVie would continue its efforts to enhance care in this disease state & other chronic, immune-mediated conditions.

Dec-2021: Leo Pharma got FDA approval for Adbry, an eczema drug. The injected antibody drug would address adults and older who don't get proper relief from topical prescription therapies. Adbry would signify important progress in LEO's aim of enhancing the standard of care in medical dermatology.

Sep-2021: Otsuka got FDA approval for Moizerto Ointment, a treatment for atopic dermatitis. Otsuka expects that Moizerto Ointment would serve as the latest treatment option for people having atopic dermatitis in Japan.

Sep-2021: Incyte got FDA approval for Opzelura, a topical JAK inhibitor to treat AD. With this approval, the company looks forward to bringing Opzelura to the patient community and also continuing to explore its potential in other skin diseases.

Scope of the Study

Market Segments covered in the Report:

By Route of Administration

• Injectable
• Oral
• Topical

By Class

• Biologics
• Calcineurin Inhibitors
• Corticosteroids
• PDE4 Inhibitors
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• Pfizer Inc.
• Sanofi SA
• AbbVie Inc.
• Galderma S.A.
• Eli Lilly and Company
• Leo Pharma A/S
• Regeneron Pharmaceuticals Inc.
• Otsuka Pharmaceutical Co. Ltd.
• Novartis AG
• Incyte Corporation

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Atopic Dermatitis Drugs Market, by Route of Administration
  • 1.4.2 Global Atopic Dermatitis Drugs Market, by Class
  • 1.4.3 Global Atopic Dermatitis Drugs Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market Overview

• 2.1 Introduction
  • 2.1.1 Overview
    • 2.1.1.1 Market Composition & Scenario
• 2.2 Key Factors Impacting the Market
  • 2.2.1 Market Drivers
  • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

• 3.1 KBV Cardinal Matrix
• 3.2 Recent Industry Wide Strategic Developments
  • 3.2.1 Acquisition and Mergers
  • 3.2.2 Approvals and Trials
• 3.3 Top Winning Strategies
  • 3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
  • 3.3.2 Key Strategic Move: (Acquisitions and Mergers : 2018, Sep - 2022, Oct) Leading Players

Chapter 4. Global Atopic Dermatitis Drugs Market by Route of Administration

• 4.1 Global Injectable Market by Region
• 4.2 Global Oral Market by Region
• 4.3 Global Topical Market by Region

Chapter 5. Global Atopic Dermatitis Drugs Market by Class

• 5.1 Global Biologics Market by Region
• 5.2 Global Calcineurin Inhibitors Market by Region
• 5.3 Global Corticosteroids Market by Region
• 5.4 Global PDE4 Inhibitors Market by Region
• 5.5 Global Others Market by Region

Chapter 6. Global Atopic Dermatitis Drugs Market by Region

• 6.1 North America Atopic Dermatitis Drugs Market
  • 6.1.1 North America Atopic Dermatitis Drugs Market by Route of Administration
    • 6.1.1.1 North America Injectable Market by Country
    • 6.1.1.2 North America Oral Market by Country
    • 6.1.1.3 North America Topical Market by Country
  • 6.1.2 North America Atopic Dermatitis Drugs Market by Class
    • 6.1.2.1 North America Biologics Market by Country
    • 6.1.2.2 North America Calcineurin Inhibitors Market by Country
    • 6.1.2.3 North America Corticosteroids Market by Country
    • 6.1.2.4 North America PDE4 Inhibitors Market by Country
    • 6.1.2.5 North America Others Market by Country
  • 6.1.3 North America Atopic Dermatitis Drugs Market by Country
    • 6.1.3.1 US Atopic Dermatitis Drugs Market
      • 6.1.3.1.1 US Atopic Dermatitis Drugs Market by Route of Administration
      • 6.1.3.1.2 US Atopic Dermatitis Drugs Market by Class
    • 6.1.3.2 Canada Atopic Dermatitis Drugs Market
      • 6.1.3.2.1 Canada Atopic Dermatitis Drugs Market by Route of Administration
      • 6.1.3.2.2 Canada Atopic Dermatitis Drugs Market by Class
    • 6.1.3.3 Mexico Atopic Dermatitis Drugs Market
      • 6.1.3.3.1 Mexico Atopic Dermatitis Drugs Market by Route of Administration
      • 6.1.3.3.2 Mexico Atopic Dermatitis Drugs Market by Class
    • 6.1.3.4 Rest of North America Atopic Dermatitis Drugs Market
      • 6.1.3.4.1 Rest of North America Atopic Dermatitis Drugs Market by Route of Administration
      • 6.1.3.4.2 Rest of North America Atopic Dermatitis Drugs Market by Class
• 6.2 Europe Atopic Dermatitis Drugs Market
  • 6.2.1 Europe Atopic Dermatitis Drugs Market by Route of Administration
    • 6.2.1.1 Europe Injectable Market by Country
    • 6.2.1.2 Europe Oral Market by Country
    • 6.2.1.3 Europe Topical Market by Country
  • 6.2.2 Europe Atopic Dermatitis Drugs Market by Class
    • 6.2.2.1 Europe Biologics Market by Country
    • 6.2.2.2 Europe Calcineurin Inhibitors Market by Country
    • 6.2.2.3 Europe Corticosteroids Market by Country
    • 6.2.2.4 Europe PDE4 Inhibitors Market by Country
    • 6.2.2.5 Europe Others Market by Country
  • 6.2.3 Europe Atopic Dermatitis Drugs Market by Country
    • 6.2.3.1 Germany Atopic Dermatitis Drugs Market
      • 6.2.3.1.1 Germany Atopic Dermatitis Drugs Market by Route of Administration
      • 6.2.3.1.2 Germany Atopic Dermatitis Drugs Market by Class
    • 6.2.3.2 UK Atopic Dermatitis Drugs Market
      • 6.2.3.2.1 UK Atopic Dermatitis Drugs Market by Route of Administration
      • 6.2.3.2.2 UK Atopic Dermatitis Drugs Market by Class
    • 6.2.3.3 France Atopic Dermatitis Drugs Market
      • 6.2.3.3.1 France Atopic Dermatitis Drugs Market by Route of Administration
      • 6.2.3.3.2 France Atopic Dermatitis Drugs Market by Class
    • 6.2.3.4 Russia Atopic Dermatitis Drugs Market
      • 6.2.3.4.1 Russia Atopic Dermatitis Drugs Market by Route of Administration
      • 6.2.3.4.2 Russia Atopic Dermatitis Drugs Market by Class
    • 6.2.3.5 Spain Atopic Dermatitis Drugs Market
      • 6.2.3.5.1 Spain Atopic Dermatitis Drugs Market by Route of Administration
      • 6.2.3.5.2 Spain Atopic Dermatitis Drugs Market by Class
    • 6.2.3.6 Italy Atopic Dermatitis Drugs Market
      • 6.2.3.6.1 Italy Atopic Dermatitis Drugs Market by Route of Administration
      • 6.2.3.6.2 Italy Atopic Dermatitis Drugs Market by Class
    • 6.2.3.7 Rest of Europe Atopic Dermatitis Drugs Market
      • 6.2.3.7.1 Rest of Europe Atopic Dermatitis Drugs Market by Route of Administration
      • 6.2.3.7.2 Rest of Europe Atopic Dermatitis Drugs Market by Class
• 6.3 Asia Pacific Atopic Dermatitis Drugs Market
  • 6.3.1 Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration
    • 6.3.1.1 Asia Pacific Injectable Market by Country
    • 6.3.1.2 Asia Pacific Oral Market by Country
    • 6.3.1.3 Asia Pacific Topical Market by Country
  • 6.3.2 Asia Pacific Atopic Dermatitis Drugs Market by Class
    • 6.3.2.1 Asia Pacific Biologics Market by Country
    • 6.3.2.2 Asia Pacific Calcineurin Inhibitors Market by Country
    • 6.3.2.3 Asia Pacific Corticosteroids Market by Country
    • 6.3.2.4 Asia Pacific PDE4 Inhibitors Market by Country
    • 6.3.2.5 Asia Pacific Others Market by Country
  • 6.3.3 Asia Pacific Atopic Dermatitis Drugs Market by Country
    • 6.3.3.1 China Atopic Dermatitis Drugs Market
      • 6.3.3.1.1 China Atopic Dermatitis Drugs Market by Route of Administration
      • 6.3.3.1.2 China Atopic Dermatitis Drugs Market by Class
    • 6.3.3.2 Japan Atopic Dermatitis Drugs Market
      • 6.3.3.2.1 Japan Atopic Dermatitis Drugs Market by Route of Administration
      • 6.3.3.2.2 Japan Atopic Dermatitis Drugs Market by Class
    • 6.3.3.3 India Atopic Dermatitis Drugs Market
      • 6.3.3.3.1 India Atopic Dermatitis Drugs Market by Route of Administration
      • 6.3.3.3.2 India Atopic Dermatitis Drugs Market by Class
    • 6.3.3.4 South Korea Atopic Dermatitis Drugs Market
      • 6.3.3.4.1 South Korea Atopic Dermatitis Drugs Market by Route of Administration
      • 6.3.3.4.2 South Korea Atopic Dermatitis Drugs Market by Class
    • 6.3.3.5 Singapore Atopic Dermatitis Drugs Market
      • 6.3.3.5.1 Singapore Atopic Dermatitis Drugs Market by Route of Administration
      • 6.3.3.5.2 Singapore Atopic Dermatitis Drugs Market by Class
    • 6.3.3.6 Malaysia Atopic Dermatitis Drugs Market
      • 6.3.3.6.1 Malaysia Atopic Dermatitis Drugs Market by Route of Administration
      • 6.3.3.6.2 Malaysia Atopic Dermatitis Drugs Market by Class
    • 6.3.3.7 Rest of Asia Pacific Atopic Dermatitis Drugs Market
      • 6.3.3.7.1 Rest of Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration
      • 6.3.3.7.2 Rest of Asia Pacific Atopic Dermatitis Drugs Market by Class
• 6.4 LAMEA Atopic Dermatitis Drugs Market
  • 6.4.1 LAMEA Atopic Dermatitis Drugs Market by Route of Administration
    • 6.4.1.1 LAMEA Injectable Market by Country
    • 6.4.1.2 LAMEA Oral Market by Country
    • 6.4.1.3 LAMEA Topical Market by Country
  • 6.4.2 LAMEA Atopic Dermatitis Drugs Market by Class
    • 6.4.2.1 LAMEA Biologics Market by Country
    • 6.4.2.2 LAMEA Calcineurin Inhibitors Market by Country
    • 6.4.2.3 LAMEA Corticosteroids Market by Country
    • 6.4.2.4 LAMEA PDE4 Inhibitors Market by Country
    • 6.4.2.5 LAMEA Others Market by Country
  • 6.4.3 LAMEA Atopic Dermatitis Drugs Market by Country
    • 6.4.3.1 Brazil Atopic Dermatitis Drugs Market
      • 6.4.3.1.1 Brazil Atopic Dermatitis Drugs Market by Route of Administration
      • 6.4.3.1.2 Brazil Atopic Dermatitis Drugs Market by Class
    • 6.4.3.2 Argentina Atopic Dermatitis Drugs Market
      • 6.4.3.2.1 Argentina Atopic Dermatitis Drugs Market by Route of Administration
      • 6.4.3.2.2 Argentina Atopic Dermatitis Drugs Market by Class
    • 6.4.3.3 UAE Atopic Dermatitis Drugs Market
      • 6.4.3.3.1 UAE Atopic Dermatitis Drugs Market by Route of Administration
      • 6.4.3.3.2 UAE Atopic Dermatitis Drugs Market by Class
    • 6.4.3.4 Saudi Arabia Atopic Dermatitis Drugs Market
      • 6.4.3.4.1 Saudi Arabia Atopic Dermatitis Drugs Market by Route of Administration
      • 6.4.3.4.2 Saudi Arabia Atopic Dermatitis Drugs Market by Class
    • 6.4.3.5 South Africa Atopic Dermatitis Drugs Market
      • 6.4.3.5.1 South Africa Atopic Dermatitis Drugs Market by Route of Administration
      • 6.4.3.5.2 South Africa Atopic Dermatitis Drugs Market by Class
    • 6.4.3.6 Nigeria Atopic Dermatitis Drugs Market
      • 6.4.3.6.1 Nigeria Atopic Dermatitis Drugs Market by Route of Administration
      • 6.4.3.6.2 Nigeria Atopic Dermatitis Drugs Market by Class
    • 6.4.3.7 Rest of LAMEA Atopic Dermatitis Drugs Market
      • 6.4.3.7.1 Rest of LAMEA Atopic Dermatitis Drugs Market by Route of Administration
      • 6.4.3.7.2 Rest of LAMEA Atopic Dermatitis Drugs Market by Class

Chapter 7. Company Profiles

• 7.1 Pfizer, Inc.
  • 7.1.1 Company Overview
  • 7.1.2 Financial Analysis
  • 7.1.3 Regional & Segmental Analysis
  • 7.1.4 Research & Development Expense
  • 7.1.5 Recent strategies and developments:
    • 7.1.5.1 Approvals and Trials:
    • 7.1.5.2 Acquisition and Mergers:
• 7.2 Novartis AG
  • 7.2.1 Company Overview
  • 7.2.2 Financial Analysis
  • 7.2.3 Segmental and Regional Analysis
  • 7.2.4 Research & Development Expense
• 7.3 Sanofi S.A.
  • 7.3.1 Company Overview
  • 7.3.2 Financial Analysis
  • 7.3.3 Segmental and Regional Analysis
  • 7.3.4 Research & Development Expense
  • 7.3.5 Recent strategies and developments:
    • 7.3.5.1 Approvals and Trials:
    • 7.3.5.2 Acquisition and Mergers:
• 7.4 LEO Pharma A/S
  • 7.4.1 Company Overview
  • 7.4.2 Financial Analysis
  • 7.4.3 Regional Analysis
  • 7.4.4 Research & Development Expense
  • 7.4.5 Recent strategies and developments:
    • 7.4.5.1 Approvals and Trials:
    • 7.4.5.2 Acquisition and Mergers:
• 7.5 Incyte Corporation
  • 7.5.1 Company Overview
  • 7.5.2 Financial Analysis
  • 7.5.3 Research & Development Expenses
  • 7.5.4 Recent strategies and developments:
    • 7.5.4.1 Approvals and Trials:
    • 7.5.4.2 Acquisition and Mergers:
• 7.6 AbbVie, Inc.
  • 7.6.1 Company Overview
  • 7.6.2 Financial Analysis
  • 7.6.3 Regional Analysis
  • 7.6.4 Research & Development Expense
  • 7.6.5 Recent strategies and developments:
    • 7.6.5.1 Approvals and Trials:
    • 7.6.5.2 Acquisition and Mergers:
• 7.7 Regeneron Pharmaceuticals, Inc.
  • 7.7.1 Company Overview
  • 7.7.2 Financial Analysis
  • 7.7.3 Research & Development Expense
• 7.8 Eli Lilly And Company
  • 7.8.1 Company Overview
  • 7.8.2 Financial Analysis
  • 7.8.3 Regional Analysis
  • 7.8.4 Research & Development Expenses
• 7.9 Otsuka Pharmaceutical Co., Ltd.
  • 7.9.1 Company Overview
  • 7.9.2 Recent strategies and developments:
    • 7.9.2.1 Approvals and Trials:
    • 7.9.2.2 Acquisition and Mergers:
• 7.10. Galderma S.A.
  • 7.10.1 Company Overview
  • 7.10.2 Recent strategies and developments:
    • 7.10.2.1 Acquisition and Mergers: